Trial Search Results

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

The purpose of this study is to provide the option of brentuximab vedotin treatment to eligible patients in studies SGN35-005 and C25001

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Seagen Inc.

Collaborator: Millennium Pharmaceuticals, Inc.

Stanford Investigator(s):


  • Drug: brentuximab vedotin


Inclusion Criteria:

   - Participated in either the SGN35-005 or C25001 clinical study and experienced
   progression. Patients who received brentuximab vedotin in C25001 must have had an
   objective response at the time of discontinuation.

   - Completed any previous treatment with radiation, chemotherapy, biologics and/or
   investigational agents at least 4 weeks prior to the first dose of brentuximab vedotin

Exclusion Criteria:

   - History of another primary malignancy that has not been in remission for at least 3

   - Known cerebral/meningeal disease

   - Peripheral neuropathy of grade 2 or greater

   - Females who are pregnant or breastfeeding

Ages Eligible for Study

6 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting